» Articles » PMID: 25754700

Epigenetic Biomarker to Support Classification into Pluripotent and Non-pluripotent Cells

Overview
Journal Sci Rep
Specialty Science
Date 2015 Mar 11
PMID 25754700
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Quality control of human induced pluripotent stem cells (iPSCs) can be performed by several methods. These methods are usually relatively labor-intensive, difficult to standardize, or they do not facilitate reliable quantification. Here, we describe a biomarker to distinguish between pluripotent and non-pluripotent cells based on DNA methylation (DNAm) levels at only three specific CpG sites. Two of these CpG sites were selected by their discriminatory power in 258 DNAm profiles - they were either methylated in pluripotent or non-pluripotent cells. The difference between these two β-values provides an Epi-Pluri-Score that was validated on independent DNAm-datasets (264 pluripotent and 1,951 non-pluripotent samples) with 99.9% specificity and 98.9% sensitivity. This score was complemented by a third CpG within the gene POU5F1 (OCT4), which better demarcates early differentiation events. We established pyrosequencing assays for the three relevant CpG sites and thereby correctly classified DNA of 12 pluripotent cell lines and 31 non-pluripotent cell lines. Furthermore, DNAm changes at these three CpGs were tracked in the course of differentiation of iPSCs towards mesenchymal stromal cells. The Epi-Pluri-Score does not give information on lineage-specific differentiation potential, but it provides a simple, reliable, and robust biomarker to support high-throughput classification into either pluripotent or non-pluripotent cells.

Citing Articles

Reassessment of marker genes in human induced pluripotent stem cells for enhanced quality control.

Dobner J, Diecke S, Krutmann J, Prigione A, Rossi A Nat Commun. 2024; 15(1):8547.

PMID: 39358374 PMC: 11447164. DOI: 10.1038/s41467-024-52922-1.


CTCF deletion alters the pluripotency and DNA methylation profile of human iPSCs.

Puri D, Maassen C, Varona Baranda M, Zeevaert K, Hahnfeld L, Hauser A Front Cell Dev Biol. 2023; 11:1302448.

PMID: 38099298 PMC: 10720430. DOI: 10.3389/fcell.2023.1302448.


Cardiac glycosides restore autophagy flux in an iPSC-derived neuronal model of WDR45 deficiency.

Papandreou A, Singh N, Gianfrancesco L, Budinger D, Barwick K, Agrotis A bioRxiv. 2023; .

PMID: 37745522 PMC: 10515824. DOI: 10.1101/2023.09.13.556416.


Automated high-content imaging in iPSC-derived neuronal progenitors.

Papandreou A, Luft C, Barral S, Kriston-Vizi J, Kurian M, Ketteler R SLAS Discov. 2023; 28(2):42-51.

PMID: 36610640 PMC: 10602900. DOI: 10.1016/j.slasd.2022.12.002.


Variation of DNA methylation on the genes is responsible for the neural differentiation propensity in human induced pluripotent stem cells.

Sekiya A, Takasawa K, Arai Y, Horike S, Akutsu H, Umezawa A Regen Ther. 2022; 21:620-630.

PMID: 36514370 PMC: 9719094. DOI: 10.1016/j.reth.2022.11.007.


References
1.
Fergus J, Quintanilla R, Lakshmipathy U . Characterizing Pluripotent Stem Cells Using the TaqMan® hPSC Scorecard(TM) Panel. Methods Mol Biol. 2014; 1307:25-37. DOI: 10.1007/7651_2014_109. View

2.
Frobel J, Hemeda H, Lenz M, Abagnale G, Joussen S, Denecke B . Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Reports. 2014; 3(3):414-22. PMC: 4266008. DOI: 10.1016/j.stemcr.2014.07.003. View

3.
Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

4.
Bibikova M, Chudin E, Wu B, Zhou L, Garcia E, Liu Y . Human embryonic stem cells have a unique epigenetic signature. Genome Res. 2006; 16(9):1075-83. PMC: 1557765. DOI: 10.1101/gr.5319906. View

5.
Smith K, Luong M, Stein G . Pluripotency: toward a gold standard for human ES and iPS cells. J Cell Physiol. 2009; 220(1):21-9. DOI: 10.1002/jcp.21681. View